Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 4,812 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,812 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $118,808.28. Following the transaction, the insider directly owned 308,831 shares in the company, valued at $7,625,037.39. The trade was a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Hims & Hers Health Trading Down 7.0%

NYSE:HIMS traded down $1.75 during trading hours on Wednesday, hitting $23.23. The stock had a trading volume of 34,826,246 shares, compared to its average volume of 35,648,238. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company has a market cap of $5.30 billion, a price-to-earnings ratio of 45.55, a P/E/G ratio of 2.42 and a beta of 2.55. The business’s 50 day moving average is $23.43 and its 200-day moving average is $37.08.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same period last year, the business posted $0.11 earnings per share. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Pathway Capital Management LP acquired a new position in Hims & Hers Health during the 3rd quarter worth approximately $6,766,000. Steadview Capital Management LLC raised its holdings in shares of Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after purchasing an additional 311,845 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after purchasing an additional 678,600 shares in the last quarter. Finally, Carnegie Investment Counsel boosted its holdings in Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock worth $17,238,000 after purchasing an additional 61,560 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the subject of several recent analyst reports. Evercore set a $24.00 price target on Hims & Hers Health in a report on Tuesday, February 24th. Leerink Partners boosted their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Monday, March 9th. Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price target for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a report on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $31.29.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Partnership with Novo Nordisk gives HIMS direct telehealth access to Ozempic and Wegovy, expanding its addressable market for weight‑loss/diabetes prescriptions and enabling a pre‑launch waitlist that could drive near‑term patient acquisition. Hims & Hers opens up pre-launch waitlist for Ozempic and Wegovy
• Positive Sentiment: The deal also resolves public friction between the companies and broadens branded GLP‑1 distribution via telehealth — a strategic win that supports HIMS’s growth narrative if conversion and pricing hold. Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
• Neutral Sentiment: Sell‑side and value commentators are highlighting HIMS as a potential long‑term beneficiary of GLP‑1 demand; these bullish previews could help sentiment but depend on execution and margin outcomes. Leerink Partners Forecasts Strong Price Appreciation for Hims & Hers Health Value Investing With Raul Shah
• Negative Sentiment: Major insider selling: COO Michael Chi sold 97,289 shares (~$2.4M) and other insiders (Soleil Boughton, Irene Becklund) also trimmed positions on Mar 17 — large insider sales can be read as a negative signal by investors even if not uncommon. SEC filings: Michael Chi Form 4 Soleil Boughton Form 4 Irene Becklund Form 4
• Negative Sentiment: GLP‑1 pricing competition is heating up (HSBC and other analysts): faster price cuts or competitive pressure from Lilly and copycat drugs could compress margins and reduce the revenue upside of greater volume. Health Care Roundup: Market Talk

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.